Across TCGA pan-cancer cohorts, GTF2E2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GTF2E2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GTF2E2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GTF2E2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where GTF2E2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.846	0.977	.006	30	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.644	.045	4	view →
PDAC	DFS	Tertile	II,III,IV	0.709	0.875	.029	2	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GTF2E2 tumor-vs-normal RNA expression · all GTF2E2 data types